NEWS

Press Releases

Media Coverage

Additional Partnerships

For all media inquiries, please contact media@tempus.com

05/08/2018
- Clinical Trials
- Genomic Sequencing
Tempus Announces New Initiative to Support Physicians Efforts to Deliver Personalized Medicine

Tempus today announced a new initiative that will allow physicians to sequence a second patient sample without additional charge, removing a barrier that oftentimes stands in the way of a patient being sequenced. The Tempus xT panel analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of...
03/20/2018
- Genomic Sequencing
Tempus Announces Additional $80 Million in Financing

Tempus announced today it has raised an additional $80M in financing. The round included existing investors, New Enterprise Associates and Revolution Growth, along with new investors Kinship Trust Company and funds advised by T. Rowe Price Associates, Inc. The additional funds will be used to further grow and...
02/22/2018
- Genomic Sequencing
Tempus Launches Tempus xE, Whole Exome Sequencing to Empower Data-Driven Cancer Care and Research

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, has launched a new genomic sequencing panel, Tempus xE, which analyzes the whole exome in a CLIA/CAP validated assay. Tempus xE, unlike most commercial panels,...
02/16/2018
- Genomic Sequencing
Tempus and the Parker Institute for Cancer Immunotherapy Work Together to Analyze Data to Help Inform Immunotherapy Treatments

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and the Parker Institute for Cancer Immunotherapy will work together to analyze clinical and molecular data to better determine which patients will have a positive response...
01/25/2018
- Genomic Sequencing
Tempus and NYU School of Medicine Announce New Initiative to Help Improve Outcomes for Pancreatic Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced a collaboration with NYU School of Medicine aimed at improving outcomes for patients diagnosed with pancreatic cancer. Pancreatic cancer is the third leading cause...
01/04/2018
- Genomic Sequencing
Tempus and Vanderbilt-Ingram Cancer Center Announce Data Initiative to Improve Outcomes for Cancer Patients

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients. As part of the initial research project, Tempus will use...
12/21/2017
- Clinical Trials
- Genomic Sequencing
CancerLinQ Engages Leading Technology Companies Tempus and Precision HealthAI to Accelerate Data-Driven Insights to Oncologists and the Cancer Care Community

CancerLinQ LLC and the data services companies Tempus and Precision HealthAI announced today they have entered into an agreement that will accelerate development and delivery of high-quality, de-identified clinical databases for use by CancerLinQ®, its oncologist subscribers, partners, and the broader cancer community. The agreement will also enable...
12/07/2017
- Genomic Sequencing
- Product Launch
Tempus Unveils Tempus O, a Platform to Structure and Annotate Clinical Data at Scale

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data today announced the launch of Tempus O, a groundbreaking system that collects, structures and analyzes clinical data from electronic medical records, research databases, images, and physician...
11/15/2017
- Genomic Sequencing
Tempus Announces Latest Immunotherapy Project

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, along with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian HealthHackensack University Medical Center announce a new...
11/01/2017
- Clinical Trials
- Genomic Sequencing
Tempus and Sanford Health Collaborate on Personalized Medicine Initiative

Tempus, a rapidly-growing technology company focused on collecting and integrating molecular and clinical data and Sanford Health, one of the largest health system in the nation will collaborate to identify targeted therapies and clinical trials for breast cancer patients. As part of the collaboration, Sanford Health will collect...

24 25 26